Abdominal Obesity Metabolic Syndrome
7
0
0
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
28.6%
2 terminated out of 7 trials
66.7%
-19.8% vs benchmark
43%
3 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (7)
Effect of Pyridoxamine Supplementation on Vascular Function and Insulin Sensitivity
A Health Promotion Project for Workers at National Taiwan University Hospital
Effects of Green-MED Diet Via the Gut-fat-brain Axis
Aldosterone Antagonism and Microvascular Function
Galantamine Effects in Patients With Metabolic Syndrome
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome
Evaluation of Liver Fibrosis in HIV-infected Patients With Metabolic Syndrome